Catalent to open new clinical supply facility in Japan
The facility will provide full-service solutions, including project management and clinical supply management, comparator sourcing, secondary packaging and labeling, clinical storage, distribution, and drug return and destruction.
Catalent Pharma Solutions is to introduce clinical supply services at its 200,000 sq. ft. cGMP facility in Kakegawa, Japan. The site, which has been providing oral drug development and manufacturing solutions for more than 40 years, will offer clinical supply solutions to meet the needs of both domestic and global clinical trial sponsors.
The facility will provide full-service solutions, including project management and clinical supply management, comparator sourcing, secondary packaging and labeling, clinical storage, distribution, and drug return and destruction. Construction has already begun at the facility and is expected to be fully validated and operational in the second quarter of 2016. The services it is to provide will complement those from Catalent’s existing footprint in Asia-Pacific, which comprise a full service primary and secondary clinical packaging and storage facility in Shanghai, a secondary packaging and clinical storage facility in Singapore, and an extensive regional depot network.
“Catalent’s site in Kakegawa will play a significant role in serving the market in Japan, the second largest pharmaceutical market worldwide and a key country for new global and domestic clinical trials,” commented Wetteny Joseph, Catalent’s President of Clinical Supply Services. “The Asia-Pacific region is a key part of our strategic growth initiatives and our site in Japan adds to Catalent’s overall clinical supply capabilities in the region, where we will continue to make investments necessary to help meet customers’ existing and future clinical trial demands.”
With facilities in the US, UK, Germany, Singapore, and China, and an extended network of over 50 audited depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, that can help to expedite clinical trials and ensure that customers are reliably supplied where and when needed around the globe.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance